SUZHOU BASECARE MEDICAL CORPORATION LIMITED Financials Suzhou Basecare Medical Corporation Limited
Equities
2170
CNE100004BC1
Healthcare Facilities & Services
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.18 HKD | +8.46% |
|
+11.79% | -7.23% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Capitalization 1 | 1,493 | 901.1 | 494.7 | 494.7 |
| Enterprise Value (EV) 1 | 2.884 | -355.5 | 567.9 | 494.7 |
| P/E ratio | -10.9 x | -6.59 x | -3.05 x | -6.32 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 13.9 x | 6.4 x | 2.73 x | 1.08 x |
| EV / Revenue | 13.9 x | 6.4 x | 2.73 x | 1.08 x |
| EV / EBITDA | -11.4 x | -7.61 x | -3.84 x | -7.73 x |
| EV / FCF | -6,585,348 x | - | - | - |
| FCF Yield | -0% | - | - | - |
| Price to Book | 0.84 x | 0.57 x | - | - |
| Nbr of stocks (in thousands) | 273,526 | 273,526 | 265,896 | 265,896 |
| Reference price 2 | 5.459 | 3.294 | 1.861 | 1.861 |
| Announcement Date | 3/30/22 | 3/30/23 | 3/28/24 | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 55.68 | 81.11 | 107.3 | 140.9 | 208 | 458.5 |
| EBITDA 1 | - | -42.07 | -131.4 | -118.3 | -128.8 | -64.03 |
| EBIT 1 | - | -48.63 | -137.2 | -126.1 | -138.7 | -76.79 |
| Operating Margin | - | -59.95% | -127.87% | -89.51% | -48.28% | -16.75% |
| Earnings before Tax (EBT) 1 | - | -881.5 | -125.7 | -126.6 | -196.3 | -78.05 |
| Net income 1 | -534 | -877.1 | -143.7 | -122.7 | -191.7 | -78.05 |
| Net margin | -958.96% | -1,081.33% | -133.88% | -87.06% | -92.17% | -17.02% |
| EPS 2 | - | -5.100 | -0.5000 | -0.5000 | -0.7000 | -0.2942 |
| Free Cash Flow | - | -72.38 | -226.8 | - | - | - |
| FCF margin | - | -89.23% | -211.33% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 9/17/20 | 3/30/21 | 3/30/22 | 3/30/23 | 3/28/24 | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 161 | 1,490 | 1,257 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -72.4 | -227 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -14.4% | -7.42% | -9.26% | -5.51% |
| ROA (Net income/ Total Assets) | - | -350% | -13.4% | -6.85% | - | - |
| Assets 1 | - | 250.7 | 1,076 | 1,790 | - | - |
| Book Value Per Share | - | 1.640 | 6.470 | 5.820 | - | - |
| Cash Flow per Share | - | -0.3700 | -0.7500 | - | - | - |
| Capex | - | 8.09 | 28.9 | - | - | - |
| Capex / Sales | - | 9.97% | 26.93% | - | - | - |
| Announcement Date | 9/17/20 | 3/30/21 | 3/30/22 | 3/30/23 | 3/28/24 | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.861
CNY
Average target price
11.18
CNY
Spread / Average Target
+501.04%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.23% | 68.27M | |
| -16.94% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -6.58% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -14.26% | 1.03B |
- Stock Market
- Equities
- 2170 Stock
- Financials Suzhou Basecare Medical Corporation Limited
